Payment overview · 2025
General Payments
$2,014.84
68 reported records · 15 companies
Healthcare provider profile · identity verified
Marcel Simo, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · RICHMOND, KY · NPI 1972734002
Verified facts
What the public records show
CMS Open Payments records show Marcel Simo, ARNP received $2,014.84 in general payments during 2025 across 68 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 15.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vivitrol by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Caplyta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $309.06 | 15.3% | 13 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $249.08 | 12.4% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $239.44 | 11.9% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $210.54 | 10.4% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $175.91 | 8.7% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $169.57 | 8.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $168.06 | 8.3% | 7 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $165.76 | 8.2% | 6 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $96.22 | 4.8% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $52.51 | 2.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.37 | 2.6% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $49.34 | 2.5% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $30.47 | 1.5% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $23.99 | 1.2% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $22.52 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,007.32 | 67 |
| Education | $7.52 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $309.06 | 13 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $249.08 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $239.44 | 10 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $210.54 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $169.57 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $168.39 | 6 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $165.76 | 6 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $144.48 | 6 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $96.22 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $52.51 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $52.37 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $49.34 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $30.47 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | VIVITROL open payments reported associated product |
CMS Open Payments — General Payments 9533 supporting records · 5661 recipient NPIs · example record 1222428584 |
Vivitrol · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 234 | 26 |
| Atorvastatin Calcium | Atorvastatin Calcium | 210 | 31 |
| Clonazepam | Clonazepam | 138 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 120 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 11 |
| Omeprazole | Omeprazole | 117 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 15 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 106 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 106 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 18 |
| Alprazolam | Alprazolam | 100 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 100 | 11 |
| Metformin Hcl | Metformin Hcl | 98 | 15 |
| Lisinopril | Lisinopril | 91 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 86 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 82 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 75 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 60 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 58 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 57 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 55 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 54 | suppressed |
| Simvastatin | Simvastatin | 54 | suppressed |
| Vraylar | Cariprazine Hcl | 54 | suppressed |
| Losartan Potassium | Losartan Potassium | 52 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 51 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 47 | suppressed |
| Furosemide | Furosemide | 45 | suppressed |
| Lamotrigine | Lamotrigine | 45 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 43 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Diazepam | Diazepam | 37 | suppressed |
| Famotidine | Famotidine | 37 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 19 |
| Atenolol | Atenolol | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Carbamazepine Er | Carbamazepine | 23 | suppressed |
| Carvedilol | Carvedilol | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 19 | 13 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 12 |
| Nystatin | Nystatin | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Caplyta | Lumateperone Tosylate | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Vivitrol | Naltrexone Microspheres | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Trulicity | Dulaglutide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,014.84 · 68 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABILIFY MAINTENA, ARISTADA, Auvelity, Azstarys, CAPLYTA, COBENFY, FANAPT, INGREZZA, LYBALVI, Natroba, Omnipod, Qelbree, REXULTI, SPRAVATO, SUBLOCADE, Spinosad, UZEDY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error